vs
Esperion Therapeutics, Inc.（ESPR）与EverCommerce Inc.（EVCM）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是EverCommerce Inc.的1.1倍（$168.4M vs $151.2M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 5.2%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 4.7%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
EverCommerce Inc.是面向服务类中小企业的领先集成SaaS解决方案提供商，核心市场覆盖北美及部分全球区域，产品线包含业务管理、支付处理、客户互动、营销工具等，服务家庭服务、健康康养、健身等多个细分领域。
ESPR vs EVCM — 直观对比
营收规模更大
ESPR
是对方的1.1倍
$151.2M
营收增速更快
ESPR
高出138.5%
5.2%
两年增速更快
ESPR
近两年复合增速
4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $151.2M |
| 净利润 | — | $6.0M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 8.8% |
| 净利率 | — | 4.0% |
| 营收同比 | 143.7% | 5.2% |
| 净利润同比 | — | 149.4% |
| 每股收益（稀释后） | $0.32 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPREVCM
| Q4 25 | $168.4M | $151.2M | ||
| Q3 25 | $87.3M | $147.5M | ||
| Q2 25 | $82.4M | $148.0M | ||
| Q1 25 | $65.0M | $142.3M | ||
| Q4 24 | $69.1M | $143.7M | ||
| Q3 24 | $51.6M | $140.1M | ||
| Q2 24 | $73.8M | $140.5M | ||
| Q1 24 | $137.7M | $137.9M |
净利润ESPREVCM
| Q4 25 | — | $6.0M | ||
| Q3 25 | $-31.3M | $11.1M | ||
| Q2 25 | $-12.7M | $8.2M | ||
| Q1 25 | $-40.5M | $-7.7M | ||
| Q4 24 | — | $-12.2M | ||
| Q3 24 | $-29.5M | $-9.2M | ||
| Q2 24 | $-61.9M | $-3.4M | ||
| Q1 24 | $61.0M | $-16.3M |
营业利润率ESPREVCM
| Q4 25 | 50.6% | 8.8% | ||
| Q3 25 | -11.4% | 10.8% | ||
| Q2 25 | 8.6% | 10.7% | ||
| Q1 25 | -34.0% | 10.0% | ||
| Q4 24 | -6.4% | 8.8% | ||
| Q3 24 | -31.0% | 7.2% | ||
| Q2 24 | 3.5% | 5.5% | ||
| Q1 24 | 52.5% | -3.1% |
净利率ESPREVCM
| Q4 25 | — | 4.0% | ||
| Q3 25 | -35.9% | 7.5% | ||
| Q2 25 | -15.4% | 5.5% | ||
| Q1 25 | -62.2% | -5.4% | ||
| Q4 24 | — | -8.5% | ||
| Q3 24 | -57.2% | -6.5% | ||
| Q2 24 | -83.9% | -2.4% | ||
| Q1 24 | 44.3% | -11.8% |
每股收益（稀释后）ESPREVCM
| Q4 25 | $0.32 | $0.04 | ||
| Q3 25 | $-0.16 | $0.06 | ||
| Q2 25 | $-0.06 | $0.04 | ||
| Q1 25 | $-0.21 | $-0.04 | ||
| Q4 24 | $-0.14 | $-0.06 | ||
| Q3 24 | $-0.15 | $-0.05 | ||
| Q2 24 | $-0.33 | $-0.02 | ||
| Q1 24 | $0.34 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $129.7M |
| 总债务越低越好 | — | $523.4M |
| 股东权益账面价值 | $-302.0M | $716.9M |
| 总资产 | $465.9M | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.73× |
8季度趋势，按日历期对齐
现金及短期投资ESPREVCM
| Q4 25 | $167.9M | $129.7M | ||
| Q3 25 | $92.4M | $106.9M | ||
| Q2 25 | $86.1M | $151.1M | ||
| Q1 25 | $114.6M | $148.4M | ||
| Q4 24 | $144.8M | $135.8M | ||
| Q3 24 | $144.7M | $101.6M | ||
| Q2 24 | $189.3M | $86.7M | ||
| Q1 24 | $226.6M | $90.0M |
总债务ESPREVCM
| Q4 25 | — | $523.4M | ||
| Q3 25 | — | $524.6M | ||
| Q2 25 | — | $525.8M | ||
| Q1 25 | — | $526.9M | ||
| Q4 24 | — | $527.9M | ||
| Q3 24 | — | $529.0M | ||
| Q2 24 | — | $530.1M | ||
| Q1 24 | — | $531.1M |
股东权益ESPREVCM
| Q4 25 | $-302.0M | $716.9M | ||
| Q3 25 | $-451.4M | $728.5M | ||
| Q2 25 | $-433.5M | $744.0M | ||
| Q1 25 | $-426.2M | $739.6M | ||
| Q4 24 | $-388.7M | $750.8M | ||
| Q3 24 | $-370.2M | $770.7M | ||
| Q2 24 | $-344.2M | $784.1M | ||
| Q1 24 | $-294.3M | $800.7M |
总资产ESPREVCM
| Q4 25 | $465.9M | $1.4B | ||
| Q3 25 | $364.0M | $1.4B | ||
| Q2 25 | $347.1M | $1.4B | ||
| Q1 25 | $324.0M | $1.4B | ||
| Q4 24 | $343.8M | $1.4B | ||
| Q3 24 | $314.1M | $1.5B | ||
| Q2 24 | $352.3M | $1.5B | ||
| Q1 24 | $373.1M | $1.5B |
负债/权益比ESPREVCM
| Q4 25 | — | 0.73× | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | 0.71× | ||
| Q4 24 | — | 0.70× | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | — | 0.66× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $21.3M |
| 自由现金流经营现金流 - 资本支出 | — | $21.0M |
| 自由现金流率自由现金流/营收 | — | 13.9% |
| 资本支出强度资本支出/营收 | 0.0% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 3.52× |
| 过去12个月自由现金流最近4个季度 | — | $109.2M |
8季度趋势，按日历期对齐
经营现金流ESPREVCM
| Q4 25 | $45.2M | $21.3M | ||
| Q3 25 | $-4.3M | $32.5M | ||
| Q2 25 | $-31.4M | $27.0M | ||
| Q1 25 | $-22.6M | $30.7M | ||
| Q4 24 | $-35.0M | $48.4M | ||
| Q3 24 | $-35.3M | $27.5M | ||
| Q2 24 | $-7.2M | $23.9M | ||
| Q1 24 | $53.8M | $13.3M |
自由现金流ESPREVCM
| Q4 25 | — | $21.0M | ||
| Q3 25 | — | $31.6M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $30.2M | ||
| Q4 24 | — | $48.2M | ||
| Q3 24 | $-35.5M | $27.4M | ||
| Q2 24 | $-7.3M | $23.3M | ||
| Q1 24 | $53.8M | $12.9M |
自由现金流率ESPREVCM
| Q4 25 | — | 13.9% | ||
| Q3 25 | — | 21.4% | ||
| Q2 25 | — | 17.9% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | — | 33.5% | ||
| Q3 24 | -68.7% | 19.5% | ||
| Q2 24 | -9.9% | 16.6% | ||
| Q1 24 | 39.0% | 9.4% |
资本支出强度ESPREVCM
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.1% | 0.3% |
现金转化率ESPREVCM
| Q4 25 | — | 3.52× | ||
| Q3 25 | — | 2.93× | ||
| Q2 25 | — | 3.31× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
EVCM
| Transferred Over Time | $146.4M | 97% |
| Transferred At Point In Time | $4.8M | 3% |
